DAVID J. MACK - 31 Aug 2025 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
Director
Signature
/s/ Richard Steinhart, Attorney-in-Fact for David J. Mack
Issuer symbol
BTAI
Transactions as of
31 Aug 2025
Net transactions value
$0
Form type
4
Filing time
02 Sep 2025, 19:00:14 UTC
Previous filing
31 Jul 2025
Next filing
01 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MACK DAVID J. Director C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, 12TH FLOOR, NEW HAVEN /s/ Richard Steinhart, Attorney-in-Fact for David J. Mack 02 Sep 2025 0001694466

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTAI Common Stock Options Exercise +1,693 +11% 16,930 31 Aug 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Restricted Stock Units Options Exercise $0 -1,693 -33% $0.000000 3,387 31 Aug 2025 Common Stock 1,693 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period.